BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 224,800 shares, an increase of 19.0% from the June 30th total of 188,900 shares. Approximately 2.9% of the shares of the stock are sold short. Based on an average daily volume of 160,500 shares, the days-to-cover ratio is presently 1.4 days.
Hedge Funds Weigh In On BioNexus Gene Lab
An institutional investor recently raised its position in BioNexus Gene Lab stock. Virtu Financial LLC grew its holdings in shares of BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 79.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 47,037 shares of the company’s stock after acquiring an additional 20,888 shares during the period. Virtu Financial LLC owned about 0.27% of BioNexus Gene Lab worth $33,000 as of its most recent SEC filing. 18.85% of the stock is owned by hedge funds and other institutional investors.
BioNexus Gene Lab Price Performance
BGLC stock traded down $0.00 during trading on Monday, reaching $0.49. 17,110 shares of the company were exchanged, compared to its average volume of 758,984. The company has a 50-day moving average of $0.49 and a two-hundred day moving average of $0.60. BioNexus Gene Lab has a twelve month low of $0.31 and a twelve month high of $3.39.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Read More
- Five stocks we like better than BioNexus Gene Lab
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Survey: Top 175 Fittest Retirement Locations in America
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Ride Out The Recession With These Dividend Kings
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.